Epicenter Stocks Reasonably Valued, Risk/Reward Best

Using seven-day comparisons, there is now steady progress in coronavirus (COVID-19) cases in the U.S. each week. I still think we need to watch day-to-day changes and spot sustained dislocations, but the trend clearly shows US COVID-19 cases are slowing.

There is also progress on the re-opening front, with more and more signs of an America returning to normalcy. Texas Gov Greg Abbott announced professional sports will allow fans to attend with 25% capacity, a major step. Walt Disney’s (DIS) re-open plans suggest the “social distance” victim businesses are proving they are finding ways to adapt. Again, American businesses are survivors and adaptable.

The market rose about 3% this short trading week, with a pronounced strong relative performance by the “epicenter” groups (Discretionary, Financials, Industrials and Energy). For the most part, it appears the US is now past the bottom on the peak on COVID-19 cases, hospitalizations and deaths, on economic fundamentals, and on equities. If these three points are correct, then this is the time for “epicenter” (aka cyclicals) to lead.

Epicenter Stocks Reasonably Valued, Risk/Reward Best

POINT #1: While daily COVID-19 cases have surging ups and downs, if we look at 7-day changes in COVID-19 reported cases, we can see sustained improvements on a week over week basis, even as testing has surged. There is still a risk of a second wave, and while we have not seen evidence of this yet, this bears watching. Nevertheless, falling positivity is suggesting this is not the trend.

POINT #2: Growing body of research shows high levels of vitamin D reduce the COVID-19 severity. Among Vitamin D benefits is a boost to the immune system. Recent studies show severe cases of COVID-19, ICU or hospitalizations, tend to have Vitamin D deficiencies. Most people get sufficient Vitamin D from sunlight and from some foods, including oily fish, like salmon, mackerel, and herring.

It turns out that a surprising 42% of Americans have vitamin D deficiency. Note that Vitamin D deficient population cohorts are similar to those suffering from severe COVID-19 outcomes. A NYC COVID-19 study published about a month ago found the following: African American- 92.3 deaths per 100,000 population; Hispanic, 74.3; White, 45.2 and Asian, 34.5. CDC risk factors for COVID-19 show many factors overlap in a striking way with those same groups with low Vitamin D deficiency: chronic lung (smoking), diabetes/obesity, heart conditions, obesity, etc. If Vitamin D plays a “silent” role in COVID-19 severity, the summer months might help prevent a second wave.

POINT #3: A CNBC interview of Larry Kudlow, NEC Director for White House (link) shows still many policy levers available. On supply chains, Kudlow spoke about ways to incentivize and also facilitate a move back to the U.S. The other subject was incentives for hard hit businesses such as restaurants; tourism; and air travel, collectively travel and expenses (T&E). Total domestic and international air travelers spent $1.1 trillion in the US in 2019, 5.5% of US GDP, with US travel 86% of the total. Our past work suggests business related travel spend is 80% of the total.

Data from a Chase Treasury presentation made a few years ago shows that air travel, lodging and restaurants make up about 70%-75% of the total expense. Using this data, and some US Chamber of Commerce estimates, we can aggregate T&E spend. Middle markets ~50%. The math is crude and based on “guesses” for number of organizations in each category. So if you would like to play with data, our data scientist, tireless Ken, is happy to send this along. Also, neither small biz nor government spending is reflected here. Both are big spenders as well. Fortune 500, which is a good proxy for S&P 500 is estimated to spend about $25 billion annually.

STRATEGY: COVID-19 Depression is a gauntlet that a cyclical business could never really prepare for, but if it survives a 40% GDP drop, with equity not diluted, doesn’t this mean that business is a lot stronger than we realized? This happened with homebuilders in 2008, and banks after the financial crisis, by the way, with survivors improving their position and share prices.

The same is probably playing out today in “epicenter stocks:”: retailers, restaurants, airlines; hotels, casinos, industrials, banks, and energy. The “epicenter” stocks that survive this is another reason to have “less barbell.” If we are correct, this will result in these stocks surprising on both EPS and with higher multiples. Epicenter stocks are only 26% of the market cap of the S&P 500, but we believe could represent 62% of the points gains in the next few quarters (see our prior comments on this).

Epicenter Stocks Reasonably Valued, Risk/Reward Best

Naturally, comparative valuation matters so we plotted the following 2021 metrics for the growth, defensive and “epicenter” groups, based on bottoms-up consensus estimates. See table.

As you can see, the “epicenter” stocks (in red) are inexpensive on a P/S basis especially compared to 2.1X for S&P 500 overall. And yet, the 2021 sales growth is forecasted to be 1.5X or better. Again, because margins are depressed, I think it is penalizing these stocks to look at EPS. Moreover, we believe 2021 EPS will surprise to the upside because of cost savings.

Additionally, growth and defensives are becoming bond “proxies,” with a fairly high correlation to bonds. Whereas, “epicenter” stocks have none. I think the valuation expansion of FANG, growth, and defensives can be explained by falling rates.

The bottom line: The “epicenter” are reasonably priced and the risk/reward best there.

Figure: Comparative matrix of risk/reward drivers in 2020
Per FS Insight

Epicenter Stocks Reasonably Valued, Risk/Reward Best

Figure: FS Insight Portfolio Strategy Summary – Relative to S&P 500
** Performance is calculated since strategy introduction, 1/10/2019

Epicenter Stocks Reasonably Valued, Risk/Reward Best
Disclosures (show)

This research is for the clients of FS Insight only. FSI Subscription entitles the subscriber to 1 user, research cannot be shared or redistributed. For additional information, please contact your sales representative or FS Insight at fsinsight.com.

Analyst Certification (Reg AC)
Tom Lee, CFA, the research analyst denoted by an “AC” on the cover of this report, hereby certifies that all of the views expressed in this report accurately reflect his personal views, which have not been influenced by considerations of the firm’s business or client relationships. Neither I, nor a member of my household is an officer, director, or advisory board member of the issuer(s) or has another significant affiliation with the issuer(s) that is/are the subject of this research report. There is a possibility that we will from time to time have long or short positions in, and buy or sell, the securities or derivatives, if any, referred to in this research.
Conflicts of Interest

This research contains the views, opinions and recommendations of FS Insight. At the time of publication of this report, FS Insight does not know of, or have reason to know of any material conflicts of interest.

General Disclosures

FS Insight is an independent research company and is not a registered investment advisor and is not acting as a broker dealer under any federal or state securities laws.

FS Insight is a member of IRC Securities’ Research Prime Services Platform. IRC Securities is a FINRA registered broker-dealer that is focused on supporting the independent research industry. Certain personnel of FS Insight (i.e. Research Analysts) are registered representatives of IRC Securities, a FINRA member firm registered as a broker-dealer with the Securities and Exchange Commission and certain state securities regulators. As registered representatives and independent contractors of IRC Securities, such personnel may receive commissions paid to or shared with IRC Securities for transactions placed by FS Insight clients directly with IRC Securities or with securities firms that may share commissions with IRC Securities in accordance with applicable SEC and FINRA requirements. IRC Securities does not distribute the research of FS Insight, which is available to select institutional clients that have engaged FS Insight.

As registered representatives of IRC Securities our analysts must follow IRC Securities’ Written Supervisory Procedures. Notable compliance policies include (1) prohibition of insider trading or the facilitation thereof, (2) maintaining client confidentiality, (3) archival of electronic communications, and (4) appropriate use of electronic communications, amongst other compliance related policies.

FS Insight does not have the same conflicts that traditional sell-side research organizations have because FS Insight (1) does not conduct any investment banking activities, and (2) does not manage any investment funds.

This communication is issued by FS Insight and/or affiliates of FS Insight. This is not a personal recommendation, nor an offer to buy or sell nor a solicitation to buy or sell any securities, investment products or other financial instruments or services. This material is distributed for general informational and educational purposes only and is not intended to constitute legal, tax, accounting or investment advice.
The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.
Intended for recipient only and not for further distribution without the consent of FS Insight.

This research is for the clients of FS Insight only. Additional information is available upon request. Information has been obtained from sources believed to be reliable, but FS Insight does not warrant its completeness or accuracy except with respect to any disclosures relative to FS Insight and the analyst’s involvement (if any) with any of the subject companies of the research. All pricing is as of the market close for the securities discussed, unless otherwise stated. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, risk tolerance, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies. The recipient of this report must make its own independent decision regarding any securities or financial instruments mentioned herein. Except in circumstances where FS Insight expressly agrees otherwise in writing, FS Insight is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice, including within the meaning of Section 15B of the Securities Exchange Act of 1934. All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client website, fsinsight.com. Not all research content is redistributed to our clients or made available to third-party aggregators or the media. Please contact your sales representative if you would like to receive any of our research publications.

Copyright © 2025 FS Insight LLC. All rights reserved. No part of this material may be reprinted, sold or redistributed without the prior written consent of FS Insight LLC.